1
|
Pamporis K, Karakasis P, Simantiris S, Sagris M, Bougioukas KI, Fragakis N, Tousoulis D. Effectiveness and safety of injectable PCSK9 inhibitors in dyslipidaemias' treatment and cardiovascular disease prevention: An overview of 86 systematic reviews and a network metaanalysis. Clin Investig Arterioscler 2024; 36:86-100. [PMID: 38040529 DOI: 10.1016/j.arteri.2023.11.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/28/2023] [Revised: 10/27/2023] [Accepted: 11/02/2023] [Indexed: 12/03/2023]
Abstract
OBJECTIVE Multiple systematic reviews (SR) have been performed on the effects of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), often providing conflicting findings. This overview and network meta-analysis (NMA) aimed to summarize SR findings on the efficacy and safety of PCSK9i and provide an updated NMA. MATERIALS AND METHODS MEDLINE (Pubmed), Scopus, Cochrane, Epistemonikos and Google Scholar were searched from inception to September 21, 2023 for SRs of randomized controlled trials (RCTs) and from January 1, 2020 to September 21, 2023 for additional RCTs. Double-independent study selection, data extraction and quality assessment were performed. Qualitative analysis was performed for SRs and a frequentist random-effects model NMA was performed for RCTs. RESULTS Totally, 86 SRs and 76 RCTs were included. Alirocumab (77/86 [90%]) and evolocumab (73/86 [85%]) were mostly analyzed. Associations from SRs (35/42 [83%]) and the updated NMA indicated PCSK9i benefit on major adverse cardiovascular events (MACEs). Reductions were also noted for cerebrovascular events (47/66 [71%]), coronary revascularization (29/33 [88%]) and myocardial infarction (41/63 [65%]). Alirocumab was associated with reductions on all-cause mortality (RR=0.82, 95%CI [0.72,0.94]). Data on any CV event reduction were conflicting (7/16 [44%]). Inclisiran appeared effective only on MACEs (RR=0.76, 95%CI [0.61,0.94]). No reductions in heart failure were observed (0/16). No increases were identified between PCSK9i and any (0/35) or serious adverse events (0/52). However, PCSK9i were associated with injection-site reactions (20/28 [71%]). CONCLUSION PCSK9i appeared to be effective in CV outcomes and their clinical application was generally safe.
Collapse
Affiliation(s)
- Konstantinos Pamporis
- 1st Cardiology Clinic, National and Kapodistrian University of Athens, School of Medicine, Hippokration General Hospital, Athens, Greece; Department of Hygiene, Social-Preventive Medicine & Medical Statistics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece.
| | - Paschalis Karakasis
- Department of Hygiene, Social-Preventive Medicine & Medical Statistics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece; Second Department of Cardiology, Hippokration General Hospital, Aristotle University of Thessaloniki, Greece
| | - Spyridon Simantiris
- 1st Cardiology Clinic, National and Kapodistrian University of Athens, School of Medicine, Hippokration General Hospital, Athens, Greece
| | - Marios Sagris
- 1st Cardiology Clinic, National and Kapodistrian University of Athens, School of Medicine, Hippokration General Hospital, Athens, Greece
| | - Konstantinos I Bougioukas
- Department of Hygiene, Social-Preventive Medicine & Medical Statistics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece
| | - Nikolaos Fragakis
- Second Department of Cardiology, Hippokration General Hospital, Aristotle University of Thessaloniki, Greece
| | - Dimitrios Tousoulis
- 1st Cardiology Clinic, National and Kapodistrian University of Athens, School of Medicine, Hippokration General Hospital, Athens, Greece
| |
Collapse
|
2
|
Pavía-López AA, Alcocer-Gamba MA, Ruiz-Gastelum ED, Mayorga-Butrón JL, Mehta R, Díaz-Aragón FA, Aldrete-Velasco JA, López-Juárez N, Cruz-Bautista I, Chávez-Mendoza A, Secchi-Nicolás NC, Guerrero-Martínez FJ, Cossio-Aranda JE, Mendoza-Zubieta V, Fanghänel-Salmon G, Valdivia-Proa M, Olmos-Domínguez L, Aguilar-Salinas CA, Dávila-Maldonado L, Vázquez-Rangel A, Pavia-Aubry V, Nava-Hernández MDLA, Hinojosa-Becerril CA, Anda-Garay JC, Ríos-Ibarra MODL, Berni-Betancourt AC, López-Cuellar J, Araiza-Garaygordobil D, Rivera-Reyes R, Borrayo-Sánchez G, Tapia-Hernández M, Cano-Nigenda CV, Guerra-López A, Elías-López J, Figueroa-Morales MA, Montaño-Velázquez BB, Velasco-Hidalgo L, Rodríguez-Lozano AL, Pimentel-Hernández C, Baquero-Hoyos MM, Romero-Moreno F, Rodríguez-Vega M. Guía de práctica clínica mexicana para el diagnóstico y tratamiento de las dislipidemias y enfermedad cardiovascular aterosclerótica. Arch Cardiol Mex 2022; 92:1-62. [PMID: 35275904 PMCID: PMC9290432 DOI: 10.24875/acm.m22000081] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2022] [Accepted: 01/14/2022] [Indexed: 11/17/2022] Open
Abstract
ANTECEDENTES Las enfermedades cardiovasculares son la principal causa mundial de mortalidad y México no es la excepción. Los datos epidemiológicos obtenidos en 1990 mostraron que los padecimientos cardiovasculares representaron el 19.8% de todas las causas de muerte en nuestro país; esta cifra se incrementó de manera significativa a un 25.5% para 2015. Diversas encuestas nacionales sugieren que más del 60% de la población adulta tiene al menos un factor de riesgo para padecer enfermedades cardiovasculares (obesidad o sobrepeso, hipertensión, tabaquismo, diabetes, dislipidemias). Por otro lado, datos de la Organización Panamericana de la Salud han relacionado el proceso de aterosclerosis como la primer causa de muerte prematura, reduciendo la expectativa de vida de manera sensible, lo que tiene una enorme repercusión social. OBJETIVO Este documento constituye la guía de práctica clínica (GPC) elaborada por iniciativa de la Sociedad Mexicana de Cardiología en colaboración con la Sociedad Mexicana de Nutrición y Endocrinología, A.C., Asociación Nacional de Cardiólogos de México, A.C., Asociación Mexicana para la Prevención de la Aterosclerosis y sus Complicaciones, A.C., Comité Normativo Nacional de Medicina General, A.C., Colegio Nacional de Medicina Geriátrica, A.C., Colegio de Medicina Interna de México, A.C., Sociedad Mexicana de Angiología y Cirugía Vascular y Endovenosa, A.C., Instituto Mexicano de Investigaciones Nefrológicas, A.C. y la Academia Mexicana de Neurología, A.C.; con el apoyo metodológico de la Agencia Iberoamericana de Desarrollo y Evaluación de Tecnologías en Salud, con la finalidad de establecer recomendaciones basadas en la mejor evidencia disponible y consensuadas por un grupo interdisciplinario de expertos. El objetivo de este documento es el de brindar recomendaciones basadas en evidencia para ayudar a los tomadores de decisión en el diagnóstico y tratamiento de las dislipidemias en nuestro país. MATERIAL Y MÉTODOS Este documento cumple con estándares internacionales de calidad, como los descritos por el Instituto de Medicina de EE.UU., el Instituto de Excelencia Clínica de Gran Bretaña, la Red Colegiada para el Desarrollo de Guías de Escocia y la Red Internacional de Guías de Práctica Clínica. Se integró un grupo multidisciplinario de expertos clínicos y metodólogos con experiencia en revisiones sistemáticas de la literatura y el desarrollo de guías de práctica clínica. Se consensuó un documento de alcances, se establecieron las preguntas clínicas relevantes, se identificó de manera exhaustiva la mejor evidencia disponible evaluada críticamente en revisiones sistemáticas de la literatura y se desarrollaron las recomendaciones clínicas. Se utilizó la metodología de Panel Delphi modificado para lograr un nivel de consenso adecuado en cada una de las recomendaciones contenidas en esta GPC. RESULTADOS Se consensuaron 23 preguntas clínicas que dieron origen a sus respectivas recomendaciones clínicas. CONCLUSIONES Esperamos que este documento contribuya a la mejor toma de decisiones clínicas y se convierta en un punto de referencia para los clínicos y pacientes en el manejo de las dislipidemias y esto contribuya a disminuir la morbilidad y mortalidad derivada de los eventos cardiovasculares ateroscleróticos en nuestro país. BACKGROUND Cardiovascular diseases are the leading cause of mortality worldwide and Mexico is no exception. The epidemiological data obtained in 1990 showed that cardiovascular diseases represented 19.8% of all causes of death in our country. This figure increased significantly to 25.5% for 2015. Some national surveys suggest that more than 60% of the adult population has at least one risk factor for cardiovascular disease (obesity or overweight, hypertension, smoking, diabetes, dyslipidemias). On the other hand, data from the Pan American Health Organization have linked the process of atherosclerosis as the first cause of premature death, significantly reducing life expectancy, which has enormous social repercussions. OBJECTIVE This document constitutes the Clinical Practice Guide (CPG) prepared at the initiative of the Mexican Society of Cardiology in collaboration with the Mexican Society of Nutrition and Endocrinology, AC, National Association of Cardiologists of Mexico, AC, Mexican Association for the Prevention of Atherosclerosis and its Complications, AC, National Normative Committee of General Medicine, AC, National College of Geriatric Medicine, AC, College of Internal Medicine of Mexico, AC, Mexican Society of Angiology and Vascular and Endovenous Surgery, AC, Mexican Institute of Research Nephrological, AC and the Mexican Academy of Neurology, A.C.; with the methodological support of the Ibero-American Agency for the Development and Evaluation of Health Technologies, in order to establish recommendations based on the best available evidence and agreed upon by an interdisciplinary group of experts. The objective of this document is to provide evidence-based recommendations to help decision makers in the diagnosis and treatment of dyslipidemias in our country. MATERIAL AND METHODS This document complies with international quality standards, such as those described by the Institute of Medicine of the USA, the Institute of Clinical Excellence of Great Britain, the Scottish Intercollegiate Guideline Network and the Guidelines International Network. A multidisciplinary group of clinical experts and methodologists with experience in systematic reviews of the literature and the development of clinical practice guidelines was formed. A scope document was agreed upon, relevant clinical questions were established, the best available evidence critically evaluated in systematic literature reviews was exhaustively identified, and clinical recommendations were developed. The modified Delphi Panel methodology was used to achieve an adequate level of consensus in each of the recommendations contained in this CPG. RESULTS 23 clinical questions were agreed upon which gave rise to their respective clinical recommendations. CONCLUSIONS We consider that this document contributes to better clinical decision-making and becomes a point of reference for clinicians and patients in the management of dyslipidemias and this contributes to reducing the morbidity and mortality derived from atherosclerotic cardiovascular events in our country.
Collapse
Affiliation(s)
| | - Marco A Alcocer-Gamba
- Sociedad Mexicana de Cardiología, Ciudad de México, México
- Facultad de Medicina, Universidad Autónoma de Querétaro, Qro., México
| | | | - José L Mayorga-Butrón
- Departamento de Posgrado, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, México
- Instituto Nacional de Pediatría, Secretaría de Salud, Ciudad de México, México
| | - Roopa Mehta
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México
| | - Filiberto A Díaz-Aragón
- Asociación Nacional de Cardiólogos de México, Ciudad de México, México
- Departamento de Posgrado, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, México
| | | | - Nitzia López-Juárez
- Unidad Médica de Alta Especialidad Hospital de Cardiología del Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México
- Sociedad Mexicana de Nutrición y Endocrinología, Ciudad de México, México
| | - Ivette Cruz-Bautista
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México
- Sociedad Mexicana de Nutrición y Endocrinología, Ciudad de México, México
| | - Adolfo Chávez-Mendoza
- Unidad Médica de Alta Especialidad Hospital de Cardiología del Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México
| | | | - Francisco J Guerrero-Martínez
- Sociedad Mexicana de Cardiología, Ciudad de México, México
- Asociación Mexicana para la Prevención de la Aterosclerosis y sus Complicaciones, Ciudad de México, México
| | | | | | - Guillermo Fanghänel-Salmon
- Asociación Mexicana para la Prevención de la Aterosclerosis y sus Complicaciones, Ciudad de México, México
| | | | - Luis Olmos-Domínguez
- Unidad Médica de Alta Especialidad Hospital de Cardiología del Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México
| | | | | | | | | | - María de Los A Nava-Hernández
- Sociedad Mexicana de Cardiología, Ciudad de México, México
- Facultad de Medicina, Universidad Autónoma de Querétaro, Qro., México
| | | | - Juan C Anda-Garay
- Colegio de Medicina Interna de México, Ciudad de México, México
- Hospital de especialidades Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Ciudad de México, México
| | | | | | | | | | - Romina Rivera-Reyes
- Sociedad Mexicana de Cardiología, Ciudad de México, México
- Facultad de Medicina, Universidad Autónoma de Querétaro, Qro., México
| | - Gabriela Borrayo-Sánchez
- Asociación Nacional de Cardiólogos de México, Ciudad de México, México
- Instituto Mexicano del Seguro Social, Ciudad de México, México
| | | | | | | | - Josué Elías-López
- Unidad Médica de Alta Especialidad Hospital de Cardiología del Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México
| | - Marco A Figueroa-Morales
- Unidad Médica de Alta Especialidad Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México
| | - Bertha B Montaño-Velázquez
- Ibero American Agency for Development & Assessment of Health Technologies (A2DAHT), Ciudad de México, México
| | | | - Ana L Rodríguez-Lozano
- Departamento de Posgrado, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, México
| | | | | | | | - Mario Rodríguez-Vega
- Ibero American Agency for Development & Assessment of Health Technologies (A2DAHT), Ciudad de México, México
| |
Collapse
|
4
|
Castro APP, Hermsdorff HHM, Milagres LC, Albuquerque FMD, Filgueiras MDS, Rocha NP, Novaes JFD. Increased ApoB/ApoA1 ratio is associated with excess weight, body adiposity, and altered lipid profile in children. J Pediatr (Rio J) 2019; 95:238-246. [PMID: 29438687 DOI: 10.1016/j.jped.2017.12.008] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/15/2017] [Revised: 12/18/2017] [Accepted: 12/26/2017] [Indexed: 11/30/2022] Open
Abstract
OBJECTIVE To investigate ApoB/ApoA1 ratio and its association with cardiovascular risk factors in children. METHODS Cross-sectional study with 258 children aged 8 and 9 years old, enrolled in all urban schools in the city of Viçosa-MG. Anthropometric and body composition assessment, as well as biochemical profile of the children was performed. Socioeconomic variables and sedentary lifestyle were evaluated through a semi-structured questionnaire. RESULTS Many children had excess weight (35.2%), abdominal adiposity (10.5%), and body fat (15.6%), as well as increased ApoB/ApoA1 ratio (14.7%), total cholesterol (51.8%), and triglycerides (19.8%). Children with excess weight and total and central fat had a higher prevalence of having a higher ApoB/ApoA1 ratio, as well as those with atherogenic lipid profile (increased LDL-c and triglycerides and low HDL-c). A direct association was found between the number of cardiovascular risk factors and the ApoB/ApoA1 ratio (p=0.001), regardless of age and income. CONCLUSION The increased ApoB/ApoA1 ratio was associated with excess weight, body adiposity (total and central), and altered lipid profile in children. Children with a higher number of cardiovascular risk factors had higher ApoB/ApoA1 ratio, in both genders.
Collapse
Affiliation(s)
| | | | | | | | | | - Naruna Pereira Rocha
- Universidade Federal de Viçosa (UFV), Departamento de Nutrição e Saúde, Viçosa, MG, Brazil
| | | |
Collapse
|
6
|
Oliveira GMMD, Mendes M, Malachias MVB, Morais J, Filho OM, Coelho AS, Capingana DP, Azevedo V, Soares I, Menete A, Ferreira B, Soares MBDPC, Fernandes M. 2017 Guidelines for the management of arterial hypertension in primary health care in Portuguese-speaking countries. Rev Port Cardiol 2017; 36:789-798. [PMID: 29162357 DOI: 10.1016/j.repc.2017.10.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2017] [Accepted: 10/09/2017] [Indexed: 10/18/2022] Open
Abstract
The World Health Organization goal's to reduce mortality due to chronic non-communicable diseases by 2% per year demands a huge effort from member countries. This challenge for health professionals requires global political action on implementation of social measures, with cost-effective population interventions to reduce chronic non-communicable diseases and their risk factors. Systemic arterial hypertension is highly prevalent in Portuguese-speaking countries, and is a major risk factor for complications such as stroke, acute myocardial infarction and chronic kidney disease, rivaling dyslipidemia and obesity in importance for the development of atherosclerotic disease. Joint actions to implement primary prevention measures can reduce outcomes related to hypertensive disease, especially ischemic heart disease and stroke. It is essential to ensure the implementation of guidelines for the management of systemic hypertension via a continuous process involving educational actions, lifestyle changes and guaranteed access to pharmacological treatment.
Collapse
Affiliation(s)
| | - Miguel Mendes
- Centro Hospitalar de Lisboa Ocidental, Hospital de Santa Cruz, Carnaxide, Portugal.
| | | | - João Morais
- Centro Hospitalar de Leiria, Hospital de Santo André, Leiria, Portugal
| | | | | | - Daniel Pires Capingana
- Universidade Cuito Cuanavale, Instituto Superior de Ciências de Saúde do Cuando Cubango, Menongue, Angola
| | - Vanda Azevedo
- Colégio da Especialidade de Cardiologia da Ordem dos Médicos de Cabo Verde, Praia, Cabo Verde
| | - Irenita Soares
- Colégio da Especialidade de Cardiologia da Ordem dos Médicos de Cabo Verde, Praia, Cabo Verde
| | - Alda Menete
- Instituto do Coração de Moçambique, Maputo, Moçambique; Colégio da Especialidade de Cardiologia da Ordem dos Médicos de Moçambique, Maputo, Moçambique
| | - Beatriz Ferreira
- Instituto do Coração de Moçambique, Maputo, Moçambique; Colégio da Especialidade de Cardiologia da Ordem dos Médicos de Moçambique, Maputo, Moçambique
| | | | | |
Collapse
|
8
|
Alves JFR, Britto RPA, Ferreira HS, Sawaya AL, Florêncio TMMT. Evolution of the biochemical profile of children treated or undergoing treatment for moderate or severe stunting: consequences of metabolic programming? J Pediatr (Rio J) 2014; 90:356-62. [PMID: 24530470 DOI: 10.1016/j.jped.2013.12.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/09/2013] [Revised: 10/09/2013] [Accepted: 10/28/2013] [Indexed: 10/25/2022] Open
Abstract
OBJECTIVE to evaluate changes in the biochemical profile of children treated or being treated for moderate or severe stunting in a nutrition recovery and education center. METHODS this was a retrospective longitudinal study of 263 children treated at this center between August of 2008 to August of 2011, aged 1 to 6 years, diagnosed with moderate (z-score of height-for-age [HAZ] < -2) or severe stunting (HAZ < -3). Data were collected on socioeconomic conditions, dietary habits, and biochemical changes, as well as height according to age. RESULTS the nutritional intervention showed an increase in HAZ of children with moderate (0.51 ± 0.4, p = 0.001) and severe (0.91 ± 0.7, p = 0.001) stunting during the monitoring. Increased levels of insulin-like growth factor 1 (IGF-1) (initial: 71.7 ng/dL; final: 90.4 ng/dL; p = 0.01) were also observed, as well as a reduction in triglycerides (TG) in both severely (initial: 91.8mg/dL; final: 79.1mg/dL; p = 0.01) and in moderately malnourished children (initial: 109.2mg/dL; final 88.7mg/dL; p = 0.01), and a significant increase in high-density lipoprotein cholesterol HDL-C only in the third year of intervention (initial: 31.4mg/dL; final: 42.2mg/dL). The values of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels remained high throughout the treatment (initial: 165.1mg/dL; final: 163.5mg/dL and initial: 109.0mg/dL; final: 107.3mg/dL, respectively). CONCLUSION the nutritional treatment for children with short stature was effective in reducing stunting and improving TG and HDL-C after three years of intervention. However, the levels of LDL-C and TC remained high even in treated children. It is therefore speculated that these changes may result from metabolic programming due to malnutrition.
Collapse
Affiliation(s)
- Jullyana F R Alves
- School of Nutrition, Universidade Federal de Alagoas (UFAL), Maceió, AL, Brazil
| | - Revilane P A Britto
- Department of Physiology, Discipline of Nutritional Physiology, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil
| | - Haroldo S Ferreira
- School of Nutrition, Universidade Federal de Alagoas (UFAL), Maceió, AL, Brazil
| | - Ana L Sawaya
- Department of Physiology, Discipline of Nutritional Physiology, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil
| | | |
Collapse
|